RepliCel's Update Shows Clinical Trial is on Track

Spotlight Companies |

RepliCel Life Sciences Inc. REPCFRepliCel Life Sciences, Inc. (REPCF) recently provided an update on its first-in-man clinical trial, TS001-2009, for a potentially revolutionary new treatment for hair loss in men and women. The highly anticipated results from the initial six-month post injection follow-up period are nearly collected.

Seventeen of the 19 subjects have had their six-month follow-up visit. During these visits, they had their overall health evaluated, including subjective and objective assessments of the verum and placebo injection sites. Digital pictures were also taken of the scalp injection sites. The remaining two patients will complete their six-month follow-ups by the end of March, while four patients should finish their 12-month follow-ups by that same time.

The TS001-2009 study team will be doing thorough reviews of the data available throughout the months of March and April this year. When completed, this will lead to the study being "un-blinded," so that the analysis team can analyze the collected data. The patients will also continue to be monitored through 2013 for any changes in their overall health.

New Treatment With Great Potential

At the core of RepliCel's revolutionary new technology is an innovative process that focuses on the regenerative properties of the dermal sheath cup cells which are found in hair follicles. By extracting the cells from a patient's healthy hair follicles--typically found in the lower area of the back of the scalp--and replicating them in a proprietary culture medium for several months, the company's scientific team believes that by re-injecting these replicated cells back into balding areas on the patient's scalp, they could potentially stimulate hair growth.

What results is a treatment that is minimally invasive and cosmetically preferable given that previous studies showed that the rejuvenated hair follicles grew in an evenly-distributed manor on SCID mice.

RepliCel Could Change Hair Loss Forever

The exciting potential of RepliCel's new treatment lies in the way it uses a patient's own hair follicles to create new hair growth. Not only does this mean getting back one's real, natural hair, but it also has applications that previous treatments lacked. In particular, the treatment has the potential to offer females who had, to this point, lacked a strong treatment option for hair loss.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
VLO Valero Energy Corporation 53.00 1.29 2.49 8,318,572

Comments

Emerging Growth

Sack Lunch Productions Inc

Sack Lunch Productions Inc is an entertainment company. The Company, through its subsidiaries, is engaged in event management, production service, film production and distribution services.

Private Markets

GoCoin

Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…